Literature DB >> 31536747

Fresh frozen plasma transfusion in patients with cirrhosis and coagulopathy: Effect on conventional coagulation tests and thrombomodulin-modified thrombin generation.

Amanda Bruder Rassi1, Elbio Antonio d'Amico1, Armando Tripodi2, Tânia Rubia Flores da Rocha1, Beatriz Yuri Migita3, Caroline Marcondes Ferreira3, Flair José Carrilho3, Alberto Queiroz Farias4.   

Abstract

BACKGROUND & AIMS: The efficacy of fresh frozen plasma (FFP) transfusion in enhancing thrombin generation in patients with cirrhosis and impaired conventional coagulation tests has not been sufficiently explored. Thus, we aimed to assess the effect of FFP transfusion on thrombin generation in these patients.
METHODS: Fifty-three consecutive patients receiving a standard dose of FFP to treat bleeding and/or before invasive procedures - if international normalized ratio (INR)/prothrombin time (PT) ratio were ≥1.5 - were prospectively enrolled. The primary endpoint was the amelioration of endogenous thrombin potential (ETP) with thrombomodulin (ETP-TM) after transfusion, which corresponds to the total amount of generated thrombin. INR/PT ratio and activated partial thromboplastin time (aPTT) were also assessed before and after transfusion.
RESULTS: FFP enhanced ETP-TM by 5.7%, from 973 (731-1,258) to 1,028 (885-1,343 nM × min; p = 0.019). Before transfusion, evidence of normal or high ETP-TM was found in 94% of patients, even in those with bacterial infections. Only 1 (1.9%) patient had ETP-TM values reverting to the normal range after transfusion. Notably, no patients with low ETP-TM had bleeding. The median decrease in ETP-TM was 8.3% and the mean was 12.8% in 18 (34%) patients after transfusion (from 1,225 [1,071-1,537] to 1,124 [812-1,370] nM × min; p ≤0.0001). Similar responses to FFP transfusion were observed in patients with compensated and acute decompensated cirrhosis, acute-on-chronic liver failure, infection or shock. FFP significantly ameliorated INR and aPTT values (p <0.0001), but in a minority of patients the values were reduced to less than the cut-off point of 1.5.
CONCLUSIONS: FFP transfusion enhanced thrombin generation and ameliorated conventional coagulation tests to normal values in a limited number of patients, and slightly decreased thrombin generation in 34% of cases. LAY
SUMMARY: Transfusion of fresh frozen plasma in patients with cirrhosis only slightly improves coagulation test values in a limited number of patients and even appears to worsen them in a third of cases. Transfusion for the purpose of preventing or treating bleeding events could cause inherent risks and costs without clear benefits.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Cirrhosis; Coagulation; Fresh frozen plasma; Thrombin generation

Mesh:

Substances:

Year:  2019        PMID: 31536747     DOI: 10.1016/j.jhep.2019.09.008

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  16 in total

1.  Rebalanced hemostasis in liver disease: a misunderstood coagulopathy.

Authors:  Lara N Roberts
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

2.  Use of FFP to correct INR: time to drop this from the decompensated cirrhosis care bundle?

Authors:  Ben Lawrence; Keith Siau
Journal:  Frontline Gastroenterol       Date:  2022-02-10

3.  Principles, Interpretation, and Evidence-Based Role of Viscoelastic Point-of-Care Coagulation Assays in Cirrhosis and Liver Failure.

Authors:  Madhumita Premkumar; Anand V Kulkarni; Kamal Kajal; Smita Divyaveer
Journal:  J Clin Exp Hepatol       Date:  2021-05-08

Review 4.  Transfusion strategies in patients with cirrhosis.

Authors:  Patricia Liu; Justine Hum; Janice Jou; Richard M Scanlan; Joseph Shatzel
Journal:  Eur J Haematol       Date:  2019-11-19       Impact factor: 2.997

5.  Fibrin clot quality in acutely ill cirrhosis patients: Relation with outcome and improvement with coagulation factor concentrates.

Authors:  Annabel Blasi; Vishal C Patel; Eva N H E Spanke; Jelle Adelmeijer; Marilena Stamouli; Ane Zamalloa; Eleanor Corcoran; Andrea Calvo; Javier Fernandez; William Bernal; Ton Lisman
Journal:  Liver Int       Date:  2021-12-20       Impact factor: 8.754

6.  Whole blood thrombin generation profiles of patients with cirrhosis explored with a near patient assay.

Authors:  Jun Wan; Lara N Roberts; Wasiliki Hendrix; Joke Konings; Tsai-Wing Ow; Liane Rabinowich; Omar Barbouti; Bas de Laat; Roopen Arya; Vishal C Patel; Mark Roest; Ton Lisman; William Bernal
Journal:  J Thromb Haemost       Date:  2020-02-18       Impact factor: 5.824

Review 7.  The hemostatic and thrombotic complications of liver disease.

Authors:  Hannah Stowe McMurry; Janice Jou; Joseph Shatzel
Journal:  Eur J Haematol       Date:  2021-07-29       Impact factor: 2.997

8.  Guidelines on the use of liver biopsy in clinical practice from the British Society of Gastroenterology, the Royal College of Radiologists and the Royal College of Pathology.

Authors:  James Neuberger; Jai Patel; Helen Caldwell; Susan Davies; Vanessa Hebditch; Coral Hollywood; Stefan Hubscher; Salil Karkhanis; Will Lester; Nicholas Roslund; Rebecca West; Judith I Wyatt; Mathis Heydtmann
Journal:  Gut       Date:  2020-05-28       Impact factor: 23.059

9.  Efficacy of pro- and anticoagulant strategies in plasma of patients undergoing hepatobiliary surgery.

Authors:  Sarah Bos; Bente van den Boom; Tsai-Wing Ow; Andreas Prachalias; Jelle Adelmeijer; Anju Phoolchund; Fraser Dunsire; Zoka Milan; Mark Roest; Nigel Heaton; William Bernal; Ton Lisman
Journal:  J Thromb Haemost       Date:  2020-09-10       Impact factor: 5.824

10.  Global hemostatic status in patients with acute-on-chronic liver failure and septics without underlying liver disease.

Authors:  Ton Lisman; Bethlehem Arefaine; Jelle Adelmeijer; Ane Zamalloa; Eleanor Corcoran; John G Smith; William Bernal; Vishal C Patel
Journal:  J Thromb Haemost       Date:  2020-11-29       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.